US 12,076,408 B2
ASGPR-binding compounds for the degradation of extracellular proteins
Mark George Saulnier, Higganum, CT (US); Jesse Jingyang Chen, Lexington, MA (US); Srinivasa Karra, Pembrooke, MA (US); Kevin Tyler Sprott, Needham, MA (US); Jason Allan Wiles, Madison, CT (US); and Soumya Ray, Quincy, MA (US)
Assigned to Avilar Therapeutics, Inc., Waltham, MA (US)
Filed by Avilar Therapeutics, Inc., Waltham, MA (US)
Filed on Jul. 11, 2023, as Appl. No. 18/220,708.
Application 18/220,708 is a continuation of application No. 17/877,538, filed on Jul. 29, 2022, granted, now 11,819,551.
Application 17/877,538 is a continuation of application No. PCT/US2021/015939, filed on Jan. 29, 2021.
Claims priority of provisional application 63/063,015, filed on Aug. 7, 2020.
Claims priority of provisional application 62/968,802, filed on Jan. 31, 2020.
Prior Publication US 2024/0072809 A1, Feb. 29, 2024
Int. Cl. C07H 9/04 (2006.01); A61K 47/54 (2017.01); A61K 47/62 (2017.01); C07H 5/06 (2006.01); C07H 7/02 (2006.01); C07H 9/02 (2006.01); C07H 15/203 (2006.01); C07H 17/00 (2006.01); C07H 17/02 (2006.01); C07H 19/02 (2006.01); C07H 19/044 (2006.01); H03L 7/081 (2006.01); H03L 7/099 (2006.01)
CPC A61K 47/549 (2017.08) [A61K 47/62 (2017.08); C07H 5/06 (2013.01); C07H 7/02 (2013.01); C07H 9/02 (2013.01); C07H 9/04 (2013.01); C07H 15/203 (2013.01); C07H 17/00 (2013.01); C07H 17/02 (2013.01); C07H 19/02 (2013.01); C07H 19/044 (2013.01); H03L 7/0814 (2013.01); H03L 7/0818 (2013.01); H03L 7/0998 (2013.01)] 26 Claims
 
1. A compound of the formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein:
R2A is selected from —NR6-heteroaryl and —NR6-aryl each of which aryl or heteroaryl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of alkyl, haloalkyl, —OR6, F, Cl, Br, —NR6R7, cyano, and C(O)R3;
R3 at each occurrence is independently selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, arylalkyl, aryl, heteroaryl, heterocycle, —OR6, and —NR8R9;
R5 is independently selected from hydrogen, heteroalkyl, C0-C6alkyl-cyano, alkyl, alkenyl, alkynyl, F, Cl, Br, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocycloalkyl, haloalkoxy, —O-alkenyl, —O-alkynyl, C0-C6alkyl-OR6, C0-C6alkyl-SR6, C0-C6alkyl-NR6R7, C0-C6alkyl-C(O)R3, C0-C6alkyl-S(O)R3, C0-C6alkyl-C(S)R3, C0-C6alkyl-S(O)2R3, C0-C6alkyl-N(R8)—C(O)R3, C0-C6alkyl-N(R8)—S(O)R3, C0-C6alkyl-N(R8)—S(O)2R3, C0-C6alkyl-O—C(O)R3, C0-C6alkyl-O—S(O)R3, C0-C6alkylN3, and C0-C6alkyl-O—S(O)2R3, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-C4alkyl, C1-C4haloalkyl, —OR6, F, Cl, Br, —NR6R7, cyano, nitro, and C(O)R3, wherein the optional substituent is selected such that a stable compound results;
R6 and R7 are independently selected at each occurrence from hydrogen, alkyl, arylalkyl, heteroarylalkyl, aryl, haloalkyl, heteroaryl, heterocycle, -alkyl-OR8, -alkyl-NR8R9, C(O)R3, S(O)R3, C(S)R3, and S(O)2R3; and
R8 and R9 are independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocycle.